Advertisement

Current Geriatrics Reports

, Volume 7, Issue 3, pp 174–180 | Cite as

Diffuse Parenchymal Lung Diseases in the Elderly

  • Sinead M. Walsh
  • Anthony W. O’Regan
Pulmonology and Respiratory Care (D Breen, Section Editor)
Part of the following topical collections:
  1. Topical Collection on Pulmonology and Respiratory Care

Abstract

Purpose of Review

Diffuse parenchymal lung diseases comprise a heterogeneous group of disorders with varying clinical, physiologic, radiographic and pathologic presentations. Age of onset varies considerably. Interstitial lung abnormalities, and in particular, idiopathic pulmonary fibrosis (IPF), occur much more commonly in older persons. In recent years, advances have been made in understanding IPF pathogenesis and changes have occurred in relation to how IPF is managed.

Recent Findings

The cause of IPF remains unclear. It is thought that a non-specific injury in susceptible individuals triggers a progressive fibrotic response. Genetic susceptibility is increasingly recognised. Multidisciplinary team input is essential for making a diagnosis. Although, originally thought to be an inflammatory process, it has been shown that anti-inflammatory therapies may, in fact, be harmful to the patient. Two anti-fibrotic therapies (pirfenidone and nintedanib) are now available. There is a better recognition of prognosis and improved symptom control and management of end of life issues.

Summary

As life expectancy increases, further studies are necessary to assess the impact and natural history of interstitial lung diseases in the elderly.

Keywords

Idiopathic Fibrosis Multidisciplinary input Anti-fibrotic therapy 

Notes

Compliance with Ethical Standards

Conflict of Interest

Sinead Walsh and Anthony O’Regan declare no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Wells AU, Kokosi MA. Subclinical interstitial lung abnormalities: toward the early detection of idiopathic pulmonary fibrosis? Am Thoracic Soc. 2016;Google Scholar
  2. 2.
    Putman RK, Hatabu H, Araki T, Gudmundsson G, Gao W, Nishino M, et al. Association between interstitial lung abnormalities and all-cause mortality. JAMA. 2016;315(7):672–81.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Araki T, Putman RK, Hatabu H, Gao W, Dupuis J, Latourelle JC, et al. Development and progression of interstitial lung abnormalities in the Framingham Heart Study. Am J Respir Crit Care Med. 2016;194(12):1514–22.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Arkema EV, Grunewald J, Kullberg S, Eklund A, Askling J. Sarcoidosis incidence and prevalence: a nationwide register-based assessment in Sweden. Eur Respir J. 2016:00477–2016.Google Scholar
  5. 5.
    •• Patterson KC, Shah RJ, Porteous MK, Christie JD, D’Errico CA, Chadwick M, et al. Interstitial lung disease in the elderly. Chest. 2017;151(4):838–44. Describes the diagnoses, clinical characteristics and outcomes of patients who were elderly at the time of ILD diagnosis. CrossRefPubMedGoogle Scholar
  6. 6.
    Castriotta RJ, Eldadah BA, Foster WM, Halter JB, Hazzard WR, Kiley JP, et al. Workshop on idiopathic pulmonary fibrosis in older adults. Chest. 2010;138(3):693–703.CrossRefPubMedPubMedCentralGoogle Scholar
  7. 7.
    Snell N, Strachan D, Hubbard R, Gibson J, Limb E, Gupta R, et al. Burden of lung disease in the UK; findings from the British Lung Foundation’s ‘respiratory health of the nation’ project. Eur Respiratory Soc; 2016.Google Scholar
  8. 8.
    Gribbin J, Hubbard RB, Le Jeune I, Smith CJ, West J, Tata LJ. Incidence and mortality of idiopathic pulmonary fibrosis and sarcoidosis in the UK. Thorax. 2006;61(11):980–5.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Schwartz D, Helmers R, Galvin J, Van Fossen D, Frees K, Dayton C, et al. Determinants of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 1994;149(2):450–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, Lynch DA, Ryu JH, Swigris JJ, Wells AU, Ancochea J, Bouros D, Carvalho C, Costabel U, Ebina M, Hansell DM, Johkoh T, Kim DS, King te Jr, Kondoh Y, Myers J, Müller NL, Nicholson AG, Richeldi L, Selman M, Dudden RF, Griss BS, Protzko SL, Schünemann HJ, ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011 2011/03/15;183(6):788–824.Google Scholar
  11. 11.
    Wolters PJ, Collard HR, Jones KD. Pathogenesis of idiopathic pulmonary fibrosis. Ann Rev Pathol: Mech Dis. 2014;9:157–79.CrossRefGoogle Scholar
  12. 12.
    Naik PK, Moore BB. Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med. 2010;4(6):759–71.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang Y, Kuan PJ, Xing C, Cronkhite JT, Torres F, Rosenblatt RL, et al. Genetic defects in surfactant protein A2 are associated with pulmonary fibrosis and lung cancer. Am J Hum Genet. 2009;84(1):52–9.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Seibold MA, Wise AL, Speer MC, Steele MP, Brown KK, Loyd JE, et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N Engl J Med. 2011;364(16):1503–12.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Armanios M. Telomerase and idiopathic pulmonary fibrosis. Mutat Res/Fundam Mol Mech Mutagen. 2012;730(1):52–8.CrossRefGoogle Scholar
  16. 16.
    Van Manen MJ, Birring SS, Vancheri C, Cottin V, Renzoni EA, Russell A-M, et al. Cough in idiopathic pulmonary fibrosis. Eur Respir Rev. 2016;25(141):278–86.CrossRefPubMedGoogle Scholar
  17. 17.
    • Lynch DA, Sverzellati N, Travis WD, Brown KK, Colby TV, Galvin JR, et al. Diagnostic criteria for idiopathic pulmonary fibrosis: a Fleischner Society White Paper. Lancet Respir Med 2017. Provides criteria to establish a confident and working diagnosis of IPF. Google Scholar
  18. 18.
    Piciucchi S, Tomassetti S, Ravaglia C, Gurioli C, Gurioli C, Dubini A, et al. From “traction bronchiectasis” to honeycombing in idiopathic pulmonary fibrosis: a spectrum of bronchiolar remodeling also in radiology? BMC Pulm Med. 2016;16(1):87.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    •• Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2071–82. IMPULSIS study is a seminal article showing improvement in outcomes with anti-fibrotic therapy (nintedanib). CrossRefPubMedGoogle Scholar
  20. 20.
    Casoni GL, Tomassetti S, Cavazza A, Colby TV, Dubini A, Ryu JH, et al. Transbronchial lung cryobiopsy in the diagnosis of fibrotic interstitial lung diseases. PLoS One. 2014;9(2):e86716.CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Lentz RJ, Argento AC, Colby TV, Rickman OB, Maldonado F. Transbronchial cryobiopsy for diffuse parenchymal lung disease: a state-of-the-art review of procedural techniques, current evidence, and future challenges. J Thorac Dis. 2017;9(7):2186–203.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Collard HR, Ryerson CJ, Corte TJ, Jenkins G, Kondoh Y, Lederer DJ, et al. Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report. Am J Respir Crit Care Med. 2016;194(3):265–75.CrossRefPubMedGoogle Scholar
  23. 23.
    Demedts M, Behr J, Buhl R, Costabel U, Dekhuijzen R, Jansen HM, et al. High-dose acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2005;353(21):2229–42.CrossRefPubMedGoogle Scholar
  24. 24.
    •• Network IPFCR. Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis. The N Engl J Med 2012;366(21):1968. PANTHER study provided evidence against using prednisolone, azathioprine and NAC in IPF patients. Google Scholar
  25. 25.
    Network IPFCR. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2093–101.CrossRefGoogle Scholar
  26. 26.
    •• King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083–92. ASCEND study is a seminal article showing improvement in outcomes with anti-fibrotic therapy (pirfenidone). CrossRefPubMedGoogle Scholar
  27. 27.
    Lee JS, Ryu JH, Elicker BM, Lydell CP, Jones KD, Wolters PJ, et al. Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;184(12):1390–4.CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Lee JS, Collard HR, Anstrom KJ, Martinez FJ, Noth I, Roberts RS, et al. Anti-acid treatment and disease progression in idiopathic pulmonary fibrosis: an analysis of data from three randomised controlled trials. Lancet Respir Med. 2013;1(5):369–76.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Kreuter M, Wuyts W, Renzoni E, Koschel D, Maher TM, Kolb M, et al. Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respir Med. 2016;4(5):381–9.CrossRefPubMedGoogle Scholar
  30. 30.
    Kistler KD, Nalysnyk L, Rotella P, Esser D. Lung transplantation in idiopathic pulmonary fibrosis: a systematic review of the literature. BMC Pulm Med. 2014;14(1):139.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Thabut G, Mal H. Outcomes after lung transplantation. J Thorac Dis. 2017;9(8):2684–91.CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    Dowman L, Hill CJ, Holland AE. Pulmonary rehabilitation for interstitial lung disease. Cochrane Libr 2014.Google Scholar
  33. 33.
    • Bell EC, Cox NS, Goh N, Glaspole I, Westall GP, Watson A, et al. Oxygen therapy for interstitial lung disease: a systematic review. Eur Respir Rev. 2017;26(143):160080. Oxygen therapy during exercise in ILD had no effects on dyspnoea, although an increase in exercise capacity was noted. CrossRefPubMedGoogle Scholar
  34. 34.
    Margaritopoulos GA, Antoniou KM, Wells AU. Comorbidities in interstitial lung diseases. Eur Respir Rev. 2017;26(143):160027.CrossRefPubMedGoogle Scholar
  35. 35.
    • Rush B, Wiskar K, Berger L, Griesdale D. The use of mechanical ventilation in patients with idiopathic pulmonary fibrosis in the United States: a nationwide retrospective cohort analysis. Respir Med. 2016;111:72–6. IPF patients who are mechanically ventilated do badly, with a mortality rate of 50%. CrossRefPubMedGoogle Scholar
  36. 36.
    • Rajala K, Lehto JT, Saarinen M, Sutinen E, Saarto T, Myllärniemi M. End-of-life care of patients with idiopathic pulmonary fibrosis. BMC Palliative Care. 2016;15(1):85. End of life decisions were made very late in patients with IPF. CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Department of Respiratory MedicineGalway University HospitalGalwayIreland
  2. 2.School of MedicineNational University of IrelandGalwayIreland

Personalised recommendations